DMAC

DiaMedica Therapeutics Inc.

Healthcare
Biotechnology
$349M market cap

Forecast run · Sep 16, 2026Upside rank 1050 of 3,149

Model Signal

ForecastQ Daily Probabilities

39.4%

49.4%

20.2%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$6.47

Price target$8.33

Implied move+28.7%

Analysts6

ForecastQ Portfolios

DMAC is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.